{"name":"CytomX Therapeutics","permalink":"cytomx-therapeutics","crunchbase_url":"http://www.crunchbase.com/company/cytomx-therapeutics","homepage_url":"http://www.cytomx.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"","phone_number":"(805) 964-9700","description":"","created_at":"Mon Sep 27 05:55:14 UTC 2010","updated_at":"Wed Aug 01 03:13:42 UTC 2012","overview":"<p>CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Our mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases. </p>","image":{"available_sizes":[[[150,51],"assets/images/resized/0010/3203/103203v1-max-150x150.jpg"],[[250,85],"assets/images/resized/0010/3203/103203v1-max-250x250.jpg"],[[293,100],"assets/images/resized/0010/3203/103203v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"CEO","person":{"first_name":"Sean","last_name":"McCarthy","permalink":"sean-mccarthy-2","image":null}},{"is_past":true,"title":"CEO","person":{"first_name":"Nancy","last_name":"E. Stagliano","permalink":"nancy-e-stagliano","image":null}},{"is_past":true,"title":"CFO","person":{"first_name":"Linda","last_name":"J. Gluck","permalink":"linda-j-gluck","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$41M","funding_rounds":[{"round_code":"b","source_url":"http://www.finsmes.com/2010/09/cytomx-therapeutics-completes-30m.html","source_description":"CytomX Therapeutics Completes $30M Series B Financing","raised_amount":30000000,"raised_currency_code":"USD","funded_year":2010,"funded_month":9,"funded_day":23,"investments":[{"company":null,"financial_org":{"name":"Third Rock Ventures","permalink":"third-rock-ventures-2","image":{"available_sizes":[[[150,78],"assets/images/resized/0005/0700/50700v1-max-150x150.png"],[[205,107],"assets/images/resized/0005/0700/50700v1-max-250x250.png"],[[205,107],"assets/images/resized/0005/0700/50700v1-max-450x450.png"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Roche Venture Fund","permalink":"roche-venture-fund","image":{"available_sizes":[[[150,21],"assets/images/resized/0004/6088/46088v1-max-150x150.jpg"],[[156,22],"assets/images/resized/0004/6088/46088v1-max-250x250.jpg"],[[156,22],"assets/images/resized/0004/6088/46088v1-max-450x450.jpg"]],"attribution":null}},"person":null}]},{"round_code":"b","source_url":"http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/07/cytomx-canaan-partners-cancer-antibodies.html","source_description":"Drug developer CytomX expands Series B by $11 million, looks to make key hires","raised_amount":11000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":7,"funded_day":31,"investments":[{"company":null,"financial_org":{"name":"Canaan Partners","permalink":"canaan-partners-3","image":{"available_sizes":[[[150,49],"assets/images/resized/0000/3958/3958v4-max-150x150.jpg"],[[250,82],"assets/images/resized/0000/3958/3958v4-max-250x250.jpg"],[[450,147],"assets/images/resized/0000/3958/3958v4-max-450x450.jpg"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"460 Ward Drive","address2":"Suite E1","zip_code":"93111","city":"Santa Barbara","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}